SE9403915D0 - Process A - Google Patents

Process A

Info

Publication number
SE9403915D0
SE9403915D0 SE9403915A SE9403915A SE9403915D0 SE 9403915 D0 SE9403915 D0 SE 9403915D0 SE 9403915 A SE9403915 A SE 9403915A SE 9403915 A SE9403915 A SE 9403915A SE 9403915 D0 SE9403915 D0 SE 9403915D0
Authority
SE
Sweden
Prior art keywords
factor viii
pct
date
recombinant
protease
Prior art date
Application number
SE9403915A
Other languages
English (en)
Original Assignee
Annelie Almstedt
Helena Sandberg
Maria Wrangel
Anna Oestlin
Anna Lisa Smeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annelie Almstedt, Helena Sandberg, Maria Wrangel, Anna Oestlin, Anna Lisa Smeds filed Critical Annelie Almstedt
Priority to SE9403915A priority Critical patent/SE9403915D0/sv
Publication of SE9403915D0 publication Critical patent/SE9403915D0/sv
Priority to CA2202875A priority patent/CA2202875C/en
Priority to US08/809,756 priority patent/US5831026A/en
Priority to JP51599396A priority patent/JP3787154B2/ja
Priority to DE69534383T priority patent/DE69534383T2/de
Priority to AT95937286T priority patent/ATE302216T1/de
Priority to AU39439/95A priority patent/AU691692B2/en
Priority to NZ295811A priority patent/NZ295811A/en
Priority to MX9703552A priority patent/MX9703552A/es
Priority to EP95937286A priority patent/EP0784633B1/en
Priority to PCT/SE1995/001351 priority patent/WO1996015150A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y10S530/831—Cohn fractions
SE9403915A 1994-11-14 1994-11-14 Process A SE9403915D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9403915A SE9403915D0 (sv) 1994-11-14 1994-11-14 Process A
PCT/SE1995/001351 WO1996015150A1 (en) 1994-11-14 1995-11-14 Process for purifying factor viii
DE69534383T DE69534383T2 (de) 1994-11-14 1995-11-14 Verfahren zur aufreinigung des faktors viii
US08/809,756 US5831026A (en) 1994-11-14 1995-11-14 Process for purifying factor VIII
JP51599396A JP3787154B2 (ja) 1994-11-14 1995-11-14 Ｖｉｉｉ因子の精製方法
CA2202875A CA2202875C (en) 1994-11-14 1995-11-14 Process for purifying factor viii
AT95937286T ATE302216T1 (de) 1994-11-14 1995-11-14 Verfahren zur aufreinigung des faktors viii
AU39439/95A AU691692B2 (en) 1994-11-14 1995-11-14 Process for purifying factor VIII
NZ295811A NZ295811A (en) 1994-11-14 1995-11-14 Protease resistant factor viii composition containing inhibitors of zinc dependent proteases added to a solution after harvest
MX9703552A MX9703552A (es) 1994-11-14 1995-11-14 Proceso de purificacion de factor viii.
EP95937286A EP0784633B1 (en) 1994-11-14 1995-11-14 Process for purifying factor viii

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9403915A SE9403915D0 (sv) 1994-11-14 1994-11-14 Process A

Publications (1)

Publication Number Publication Date
SE9403915D0 true SE9403915D0 (sv) 1994-11-14

Family

ID=20395964

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9403915A SE9403915D0 (sv) 1994-11-14 1994-11-14 Process A

Country Status (11)

Country Link
US (1) US5831026A (sv)
EP (1) EP0784633B1 (sv)
JP (1) JP3787154B2 (sv)
AT (1) ATE302216T1 (sv)
AU (1) AU691692B2 (sv)
CA (1) CA2202875C (sv)
DE (1) DE69534383T2 (sv)
MX (1) MX9703552A (sv)
NZ (1) NZ295811A (sv)
SE (1) SE9403915D0 (sv)
WO (1) WO1996015150A1 (sv)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605222B1 (en) * 1998-05-20 2003-08-12 Baxter Aktiengesellschaft Method for producing a factor VIII/von Willebrand factor complex
US6586573B1 (en) 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
EP1172443A4 (en) * 1999-03-19 2004-11-17 Yamanouchi Pharma Co Ltd METHOD FOR SCREENING AN INHIBITOR OF THE CYSTEIN PROTEASE
US6338964B1 (en) * 1999-05-07 2002-01-15 Bayer Corporation Process and medium for mammalian cell culture under low dissolved carbon dioxide concentration
HUP0402315A3 (en) * 2001-12-21 2009-03-30 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
EP1605968A2 (en) * 2003-03-18 2005-12-21 Novo Nordisk Health Care AG Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) * 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
ES2335994T3 (es) * 2003-07-01 2010-04-07 Novo Nordisk Health Care Ag Composicion farmaceutica liquida, acuosa de polipeptidos factor vii.
JP5653572B2 (ja) * 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
KR20150138427A (ko) * 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
WO2008135498A2 (en) * 2007-05-04 2008-11-13 Novo Nordisk A/S Prevention of protein degradation in mammalian cell cultures
EP2113564A1 (en) * 2008-05-01 2009-11-04 Arecor Limited Protein formulation
US8329871B2 (en) * 2008-06-24 2012-12-11 Octapharma Ag Process of purifying coagulation factor VIII
WO2010020690A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
ATE551050T1 (de) * 2008-09-03 2012-04-15 Octapharma Ag Stabilisierte zusammensetzungen für rekombinant hergestellten faktor viii
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
BRPI1105317A2 (pt) 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289691A (en) * 1980-01-18 1981-09-15 The Canadian Red Cross Society Method of obtaining intermediate purity factor VIII
US4406886A (en) * 1983-01-14 1983-09-27 University Patents, Inc. Purification of antihemophilia factor VIII by precipitation with zinc ions
FI86885C (sv) * 1984-04-20 1992-10-26 Genentech Inc Förfarande för framställning av human rekombinantfaktor VIII och nukle insyrasekvenser och vektorer använd därtill
US5149787A (en) * 1984-05-22 1992-09-22 The Blood Center Research Foundation Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4710381A (en) * 1984-05-22 1987-12-01 The Blood Center Of Southeastern Wisconsin Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4981951A (en) * 1988-04-14 1991-01-01 Miles Inc. Lectin affinity chromatography of factor VIII
WO1990002175A1 (en) * 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
IT1248723B (it) * 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
EP0575405A1 (en) * 1991-02-04 1993-12-29 Berlex Laboratories, Inc. Endothelin converting enzyme
SE468050C (sv) * 1991-03-15 1998-02-11 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
CA2078721A1 (en) * 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
US5278289A (en) * 1991-11-12 1994-01-11 Johnson Alan J Antihemophilic factor stabilization
US5399670A (en) * 1992-04-30 1995-03-21 Alpha Therapeutic Corporation Solubilization and stabilization of factor VIII complex
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
GB9211538D0 (en) * 1992-06-01 1992-07-15 Blake David R Antiinflammatory agent
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration

Also Published As

Publication number Publication date
WO1996015150A1 (en) 1996-05-23
JP3787154B2 (ja) 2006-06-21
NZ295811A (en) 1998-08-26
AU3943995A (en) 1996-06-06
US5831026A (en) 1998-11-03
EP0784633A1 (en) 1997-07-23
CA2202875C (en) 2011-03-15
CA2202875A1 (en) 1996-05-23
EP0784633B1 (en) 2005-08-17
JPH10509144A (ja) 1998-09-08
ATE302216T1 (de) 2005-09-15
MX9703552A (es) 1997-08-30
AU691692B2 (en) 1998-05-21
DE69534383T2 (de) 2006-05-24
DE69534383D1 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
SE9403915D0 (sv) Process A
DE69207920T2 (de) Stabilisierte persäurelösungen
ES2072452T3 (es) Medios cosmeticos desodorizantes.
ES2177581T3 (es) Uso de compuestos de piperidina en el tratamiento de esquizofrenia.
ATE169445T1 (de) Verwendung von gelformulierungen als beizmittel
MX9703445A (es) Material absorbente.
BR9712792A (pt) Inibidores de metaloprotease bidentada.
ES2142490T3 (es) Ciclopeptolidos.
Ruenwongsa et al. Acidic protease from human seminal plasma. Purification and some properties of active enzyme and of proenzyme.
DE59002760D1 (de) K2p pro-stabilisierung.
NO2006006I1 (no) Aktivert protein C
IT1169774B (it) Composizioni terapeutiche iniettabili contenenti sali stabili della s-adenosil-l-metionina
DE69632629D1 (de) Thrombin zusammensetzung
DE69227805T2 (de) Verwendung von Tri-n-Butylphosphat bei niedrigem pH in Lösungen von biologisch aktiven Proteinen für eine verbesserte viruzide Wirkung
FI853962L (fi) Buffrade glutaraldehyd innehaollande steriliserande och desinficerande kompositioner.
PT806206E (pt) Composicoes aquosas que contem ciprofloxacina e utilizacao e processo correspondentes
Ikeno et al. Effects of prolonged parotid duct ligation, parotidectomy and acute hepatitis of rats on amylase activity
ATE356220T1 (de) Verfahren zur enzymatischen herstellung von fructosylverbindungen
SU1205553A1 (ru) Способ получения глутамин(аспарагин)азы из pseudomonas aurantiaca вкмв-548